Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

@article{Patil2007ActivationOM,
  title={Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial},
  author={Sandeep T Patil and Lu Zhang and Ferenc Mart{\'e}nyi and Stephen Loucian Lowe and Kimberley Jackson and Boris V. Andreev and Alla Avedisova and Leonid M Bardenstein and Issak Y Gurovich and Margarita A. Morozova and Sergey N. Mosolov and Nikolai G Neznanov and Alexander M Reznik and A B Smulevich and Vladimir A Tochilov and Bryan G. Johnson and James A. Monn and Darryle D. Schoepp},
  journal={Nature Medicine},
  year={2007},
  volume={13},
  pages={1102-1107}
}
Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological features of disrupted neuronal excitability and plasticity within limbic structures of the brain. These pathological features manifest behaviorally as positive symptoms (including hallucinations, delusions and thought disorder), negative symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathological symptoms (such as psychomotor retardation, lack of insight, poor attention… Expand
mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial
Anomalies in glutamatergic neurotransmission are currently believed to be one of the pathogenetic factors in schizophrenia and dopamine antagonists are increasingly widely used in medicine asExpand
Identification of a Novel Serotonin / Glutamate Receptor Complex Implicated in Psychosis
The psychosis associated with schizophrenia is characterized by alterations in sensory processing and perception1,2. Some antipsychotic drugs were identified by their high affinity for serotoninExpand
Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery
TLDR
The present review summarizes the results of the latest papers, showing that the simultaneous activation of two receptors with sub-effective doses of their ligands induces similar effects as the highest dose of each compound alone. Expand
[The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].
TLDR
The results suggest that the agonist for 2/3 (mGlu2/3) receptors has antipsychotic properties and provides a new, alternative to dopamine agonists, method for pharmacotherapy of schizophrenia. Expand
Promise of mGluR2/3 activators in psychiatry
TLDR
Clinical studies reveal that group II mGluR agonists have robust efficacy in human models of panic attack and fear-potentiated startle and improve ratings for positive and negative symptoms in patients suffering from schizophrenia (Patil et al, 2007). Expand
Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs
TLDR
It has been recently suggested that this apparent lack of efficacy in schizophrenic patients may be related to previous exposure to atypical antipsychotics, and the role of the functional heterocomplex formed by 5-HT2A and mGlu2 receptors in the clinical response to Group II mGLUR agonists is currently under study. Expand
Identification of a serotonin/glutamate receptor complex implicated in psychosis
TLDR
It is shown that the mGluR2 interacts through specific transmembrane helix domains with the 2AR, a member of an unrelated G-protein-coupled receptor family, to form functional complexes in brain cortex that may be involved in the altered cortical processes of schizophrenia. Expand
Metabotropic Glutamate Receptor 2 Activators
TLDR
Modulation of the metabotropic glutamate type 2 (mGlu2) receptor has emerged as a promising mechanism for the treatment of CNS diseases, with the potential to provide a new and more effective avenue for the Treatment of schizophrenia. Expand
Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
TLDR
Emerging preclinical and clinical data suggest that activation of group II mGlu receptors is a mechanistically novel and promising approach for the treatment of schizophrenia. Expand
Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?
TLDR
It is argued that it would be a great mistake to terminate the study of mGluR2/3 as a therapeutic target for schizophrenia, and the comprehensive features of the translational potential mGlamorganic glutamate receptor agonists as well as the need for further research into the more selective activation of mR2. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
  • D. Dd, G. Marek
  • Medicine
  • Current drug targets. CNS and neurological disorders
  • 2002
TLDR
Clinical studies with mGlu2/3 agonists may be warranted to further explore the validity of the glutamatergic hypothesis of schizophrenia, which has been implicated in psychotic states and possibly in the etiology of schizophrenia. Expand
The potential role of lamotrigine in schizophrenia
TLDR
The efficacy of lamotrigine is most likely explained within the framework of a glutamate neuron dysregulation hypothesis, and may arise primarily through the drugs ability to influence glutamate transmission and neural activity in the cortex. Expand
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
TLDR
This review focuses on two brain regions, the locus coeruleus and the cerebral cortex, where the actions of indoleamine and the phenethylamine hallucinogen have been shown to be mediated by 5-HT(2A) receptors; in each case, the hallucinogens have been found to enhance glutamatergic transmission. Expand
Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors
TLDR
The results of the present experiments raise the possibility that the psychomimetic properties of hallucinogenic drugs may be mediated in part, via increased glutamate release following activation of 5-HT2A receptors. Expand
Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
TLDR
In the current limited data set, a moderate amelioration of negative symptoms of schizophrenia was found, but no other statistically significant beneficial effects on Symptoms of schizophrenia are found. Expand
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
TLDR
Findings indicate that risperidone and olanzapine efficacy might be augmented with D-serine adjuvant treatment, and confirm D-Serine efficacy against main schizophrenia symptom domains, warrant the assessment of D- Serine antipsychotic monotherapy for this illness. Expand
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
TLDR
Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model, and an agonist of this group of receptors attenuated the disruptive effects of Phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. Expand
The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
TLDR
The marked mGlu2/3 receptor-mediated inhibitions of PCP-evoked behaviors by LY354740 and LY379268, with minimal effects on AMP, may indicate potential antipsychotic effects in humans in the absence of dopamine mediated extrapyramidal side effects. Expand
Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia
TLDR
Preliminary findings support the hypothesis that lamotrigine adjuvant treatment may improve positive symptoms and general psychopathology in schizophrenia, and suggest that beneficial effects may be achieved when lamOTrigine is added to both conventional and atypical antipsychotics, and warrant additional, larger scale trials. Expand
Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.
TLDR
The present review gives a comprehensive overview of the knowledge (and the lack of knowledge) with respect to the clinical and preclinical effects of neuroleptic drugs and tries to integrate this knowledge in order to identify the neuronal mechanisms underlying the therapeutic and side effects of Neuroleptic Drugs. Expand
...
1
2
3
4
5
...